Insider Information
Antisense Pharma latest news
2010/11/20 - SNO Scientific Meeting and Education Day in Montreal, Canada - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/11/16-19 - 22nd ENA in Berlin - Antisense Pharma presents data on preclinical studies with trabedersen (AP 12009)
2010/09/16-19 - 9th EANO in Maastricht - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/07/08 - Annual Meeting Japanese Association of Molecular Target Therapy of Cancer in Tokyo, Japan - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/07/01 - ESMO Conference: 12th World Congress on Gastrointestinal Cancer in Barcelona - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/06/28-29 - 5th smi conference on RNAi, siRNA und miRNA in London- Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/06/4-8 - ASCO Annual Meeting in Chicago - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2010/04/17-21 - AACR 101st Annual Meeting in Washington - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2009/10/22-24 -Joint Meeting of the "Society for Neuro-Oncology" (SNO) and the Tumor Section of the "American Association of Neurological Surgeons" (AANS)/ "Congress of Neurological Surgeons" (CNS) in New Orleans, Louisiana- Antisense Pharma presents data on clinical studies with trabedersen
2009/10/06-07 - Science to Market - "European Association of Pharma Biotechnology" (EAPB) Conference during Biotechnica in Hannover, Germany - Antisense Pharma presents data on clinical studies with trabedersen
2009/09/24-26 German Skin Cancer Congress in Cologne -Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2009/09/20-24 ECCO ESMO Multidisciplinary Congress in Berlin - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2009/06/25-06/26 NOA - 11th Annual Meeting of the "Neuroonkologische Arbeitsgesellschaft" in Heidelberg, Germany -Antisense Pharma presents data on clinical studies with trabedersen (AP 12009
2009/06/11-06/13 - 21st Pezcoller Symposium, Trento, Italy - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
2009/05/29-06/02 - ASCO - Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida - Antisense Pharma presents data on clinical studies with trabedersen (AP 12009)
Top News

August 2010. The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma.
This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies. Within the IND-authorisation, the FDA also agreed that trabedersen may be administered with an innovative application system, developed by Antisense Pharma, via CED (Convection Enhanced Delivery).

Further information is available here.

 
 

For all media inquiries:

Carolin Nolte
Public and Investor Relations
Phone: +49-941-92013-0
E-Mail: pr@antisense-pharma.com

Our corporate news is available as pdf-downloads in the section press releases.